Dr. Mary Tolikas has more than twenty years of professional experience establishing and growing technology-based organisations and companies in both industry and academia.
Dr. Mary Tolikas joined the Wyss Center as Chief Executive Officer in June 2019. She was previously instrumental in the launching and growth of the Wyss Institute for Biologically Inspired Engineering at Harvard University where she spent almost ten years in the leadership team as Operations Director.
During her tenure at Harvard University, she also served as Executive Director for Special Projects at the Office of the Provost and was co-instructor in the Masters in Design Engineering Program, offered by the Harvard John A. Paulson School of Engineering and Applied Sciences and the Harvard Graduate School of Design.
Prior to joining Harvard University, Dr. Mary Tolikas served as Director of Business Development at Ansoft Corporation. Earlier in her career, she held various executive and engineering roles in a number of start-up companies in markets ranging from automotive to medical.
Dr. Mary Tolikas has served in numerous committees and boards but her most rewarding community involvement is mentoring women in science and engineering, as well as entrepreneurs.
She holds a B.Eng. degree in Electrical & Electronics Engineering from the University of Glasgow, Scotland, M.Sc. and Ph.D. degrees in Electrical Engineering & Computer Science from the Massachusetts Institute of Technology and an MBA degree from the Sloan School of Management at MIT.
Subscribe to our updates
Swiss Science celebrates Hansjörg Wyss
Today, Hansjörg Wyss received the Gallatin Award from the Swiss American Chamber of Commerce for his great commitments to the science landscape in Switzerland.Wyss Center
Completely locked-in man uses brain-computer interface to communicate
Two-year study paves the way for new technologies for people with severe paralysisTechnology
GliaPharm SA and the Wyss Center enter collaboration to develop new therapies for Alzheimer’s disease
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkersCollaboration